about
Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) studyInterlaboratory reproducibility of the immunocytochemical assessment of oestrogen and progesterone receptors and proliferative activity in fine needle aspiration of breast cancer.Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24: results at recruitmentThe effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600)A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 yearsComparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial.hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopyComparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.Analysis of morphologic patterns of fine-needle aspiration of the breast to reduce false-negative results in breast cytology.HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies.Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testingHPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology.Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study).Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.Type-specific human papillomavirus biological features: validated model-based estimatesHPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women.Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology.Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference.A first survey of HPV-based screening in routine cervical cancer screening in Italy.Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011-2012 activity.hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme.Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening.The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials.Analysis of false-negative and underreported smears in the Florence district screening program for cervical carcinoma.Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix.Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT.Four-year results of low-dose CT screening and nodule management in the ITALUNG trial.Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure.Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.Does UKLS strategy increase the yield of screen-detected lung cancers? A comparison with ITALUNG.Reduced and Full-Preparation CT Colonography, Fecal Immunochemical Test, and Colonoscopy for Population Screening of Colorectal Cancer: A Randomized Trial.Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion.Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.Technical evaluation of the new thin layer device CellSlide (Menarini Diagnostics).
P50
Q30651813-4EEA5AA6-3644-43DC-A165-71D44C16CA8EQ30832008-2E81554F-82BC-490C-B3E5-19106B3AF611Q33596805-CC960CF6-A9D1-44E2-A77E-F4B38BD35729Q34543764-E9706C4A-CFAA-4D7C-8088-347977FA365DQ34580264-9F549D85-C97A-40B9-A47D-FEC35F41136AQ34719578-E29CF9B4-31C7-4C4D-A191-930F6818E47CQ34739688-ACD9505A-148C-43F9-A554-44B4FD41FBBFQ34979227-0E1BB1C2-AEA3-4C75-8326-9AA80F120A16Q35066980-13FB8670-EB0D-42B2-AB61-72BF6B95EBD3Q36110685-F3F36BA5-0921-4594-8BD4-0AC3D78BA27FQ36480261-A63C6C6E-5566-4C4D-AA6B-5EFFED94D77AQ36621498-8911B4A2-4F1E-4CC2-AAD1-1C3FB47688C2Q36708180-3720A0F8-5F37-4A00-ABAD-79F85C226C54Q36744627-E2928835-64EC-4B68-A2E4-70ED542B49F1Q37265745-802DB233-55B3-46E1-8BF7-4854650AF337Q37439328-13912164-04B9-499E-8A39-F706AFAB7D33Q38669823-5E8B4612-B94E-4512-8B2C-697098837642Q40251694-85D57CE5-0951-4BF9-BF89-90E9C59A2D4AQ40358326-443F65A7-1061-48AD-A5C4-7E4528E6CC94Q40432574-61DF08A7-663D-4CD7-8D33-38522A3D0064Q40502667-EB2B8C93-71F7-4D36-944F-C0D37B166E6BQ40502674-8B18A4F2-CA8D-4098-9CE8-8ED5F871CFCDQ40982323-06DBDB40-BD00-459B-ACD3-45F939F9D5D0Q41548112-7C06E12E-A39C-4DAE-965C-B06ED17A7110Q41644873-0A44E365-D0B9-46EF-B212-B519E6712901Q41651390-37A0B04D-7127-46AE-902F-D9C81E387FD1Q41708475-03F3BD6E-5D81-4687-B2FA-CFF1751F0D00Q41731838-29A28E97-7DDF-4B97-8213-C578A75CA73AQ42219536-BCD63993-C676-46AE-A09E-ACC36A7602A1Q43984788-0B7EB61A-7DFC-493C-98CE-36A74D98B0A1Q44119126-716DB99D-8D95-4B63-B11F-17F88EF7E972Q45080408-503CB911-512C-4EA7-A413-AD655923F555Q45256991-CD26A43C-4288-4161-A55E-2ED0398DFBA4Q45618486-0C3B496F-463D-4C92-ADDF-6C28681CC0C2Q49165143-09B8A67D-0F09-4709-904D-454CD2656D63Q50850054-145371DE-F5C6-457D-9FB4-26170641FA11Q50896775-6CB02050-198C-4A86-8D97-335D406F049EQ50965956-E12ACEF6-3078-4AC5-B130-7E2350DBDABCQ51201676-3461644E-5455-47B8-9B08-8B010D74BC53Q51317040-CECDEE64-3144-4BD8-B00A-D867830BCBDA
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesca M Carozzi
@ast
Francesca M Carozzi
@en
Francesca M Carozzi
@es
Francesca M Carozzi
@nl
type
label
Francesca M Carozzi
@ast
Francesca M Carozzi
@en
Francesca M Carozzi
@es
Francesca M Carozzi
@nl
altLabel
Francesca Carozzi
@en
Francesca Maria Carozzi
@en
prefLabel
Francesca M Carozzi
@ast
Francesca M Carozzi
@en
Francesca M Carozzi
@es
Francesca M Carozzi
@nl
P106
P21
P31
P496
0000-0002-7162-8781